1 Min Read
Jan 4 (Reuters) - Merck & Co Inc:
* LYCERA CORP ANNOUNCES INITIATION OF PHASE 1B STUDY OF NOVEL IMMUNO-ONCOLOGY CANDIDATE LYC-55716 IN COMBINATION WITH PEMBROLIZUMAB Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.